TUCSON, AZ -- (Marketwire) -- 04/28/11 -- On April 13, SynCardia Systems, Inc., manufacturer of the SynCardia temporary Total Artificial Heart, presented awards to seven SynCardia Certified Centers during its Clinical Investigator meeting in San Diego for its FDA-approved Investigational Device Exemption (IDE) clinical study of the Freedom® portable driver. The 13.5-lb Freedom driver, which is also CE approved for use in Europe, is the world's first wearable driver designed to power the Total Artificial Heart both inside and outside the hospital.
Outstanding Outcomes Award
Freedom® Pioneer Award
Best Launch Award
CAUTION -- The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the Total is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. More than 900 implants account for more than 210 patient years of life.
Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.
In March 2011, Fast Company magazine ranked SynCardia #20 among the World's 50 Most Innovative Companies "for giving mobility to artificial heart recipients."
For additional information, please visit: http://www.syncardia.com
or follow SynCardia on Twitter - @SynCardia_News
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1592039
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=1592036
Media Contact:
Don Isaacs
Vice President of Communications
SynCardia Systems, Inc.
Cell: (520) 955-0660